Biying Xu

Affiliations: 
2019 University of Texas at Austin, Austin, Texas, U.S.A. 
Google:
"Biying Xu"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kurebayashi Y, Olkowski CP, Lane KC, et al. (2021) Rapid Depletion of Intratumoral Regulatory T cells Induces Synchronized CD8 T and NK Cell Activation and IFN-γ-dependent Tumor Vessel Regression. Cancer Research
Xu B, Tang J, Lyu C, et al. (2020) Regulated Tristetraprolin Overexpression Dampens the Development and Pathogenesis of Experimental Autoimmune Uveitis. Frontiers in Immunology. 11: 583510
Napier RJ, Lee EJ, Davey MP, et al. (2020) T cell-intrinsic role for Nod2 in protection against Th17-mediated uveitis. Nature Communications. 11: 5406
Bing SJ, Lyu C, Xu B, et al. (2020) Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Molecular Vision. 26: 641-651
Chen H, Liu M, Xu B, et al. (2020) MAGICAL: An Open-Source Fully Automated Analog IC Layout System from Netlist to GDSII Ieee Design & Test of Computers. 1-1
Zhao W, Li S, Xu B, et al. (2020) A 0.025-mm 2 0.8-V 78.5-dB SNDR VCO-Based Sensor Readout Circuit in a Hybrid PLL- $\Delta\Sigma$ M Structure Ieee Journal of Solid-State Circuits. 55: 666-679
Jagoda EM, Vasalatiy O, Basuli F, et al. (2019) Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Molecular Imaging. 18: 1536012119829986
Roy J, Kuo F, Basuli F, et al. (2019) The Distribution Volume of F-Albumin as a Potential Biomarker of Antiangiogenic Treatment Efficacy. Cancer Biotherapy & Radiopharmaceuticals
McWilliams IL, Kielczewski JL, Ireland DDC, et al. (2019) Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. Cell Reports. 26: 1718-1726.e4
Lyu C, Bing SJ, Wandu WS, et al. (2018) TMP778, a selective inhibitor of RORγt, suppresses experimental autoimmune uveitis development, but affects both Th17 and Th1 cell populations. European Journal of Immunology
See more...